PP 37
INTEGRATED EFFICACY RESULTS FROM THE PHASE 2 AND PHASE 3 STUDIES WITH CAPLACIZUMAB IN PATIENTS WITH ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA
Flora Peyvandi1, Spero Cataland2, Marie Scully3, Paul Coppo4, Paul Knoebl5, Johanna A. Kremer Hovinga6, Ara Metjian7, Javier de la Rubia8, Katerina Pavenski9, Jessica Minkue Mi Edou10, Filip Callewaert11, Hilde De Winter12
1 Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, and Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, Italy
2 Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA
3 Department of Haematology, University College London Hospitals NHS Trust, London, UK
4 Department of Hematology, Reference Center for Thrombotic Microangiopathies (CNR-MAT), Saint-Antoine University Hospital, AP-HP, Paris, France
5 Department of Medicine 1, Division of Hematology and Hemostasis, Medical University of Vienna, Austria
6 Department of Hematology and Central Hematology Laboratory, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland
7 Division of Hematology, Department of Medicine, University of Colorado–Anschutz Medical Center, Denver, CO, USA
8 Hematology Department, Internal Medicine, School of Medicine and Dentistry, Catholic University of Valencia and Hospital Doctor Peset, Valencia, Spain
9 Departments of Medicine and Laboratory Medicine, St. Michael's Hospital and University of Toronto, Toronto, ON, Canada
10 Clinical Development, Ablynx, a Sanofi company, Ghent, Belgium
11 Medical Affairs, Sanofi, Diegem, Belgium
12 Formerly Clinical Development, Ablynx, a Sanofi company, Ghent, Belgium
Ver másRead
2175
Timeswas read the article
962
Total PDF
1213
Total HTML
| Year/Month | Html | Total | |
|---|---|---|---|
| 2025 6 | 17 | 5 | 22 |
| 2025 5 | 40 | 12 | 52 |
| 2025 4 | 39 | 16 | 55 |
| 2025 3 | 51 | 11 | 62 |
| 2025 2 | 42 | 24 | 66 |
| 2025 1 | 32 | 24 | 56 |
| 2024 12 | 25 | 17 | 42 |
| 2024 11 | 26 | 26 | 52 |
| 2024 10 | 32 | 27 | 59 |
| 2024 9 | 35 | 25 | 60 |
| 2024 8 | 40 | 31 | 71 |
| 2024 7 | 25 | 28 | 53 |
| 2024 6 | 32 | 23 | 55 |
| 2024 5 | 31 | 25 | 56 |
| 2024 4 | 26 | 26 | 52 |
| 2024 3 | 28 | 24 | 52 |
| 2024 2 | 27 | 29 | 56 |
| 2024 1 | 26 | 23 | 49 |
| 2023 12 | 24 | 21 | 45 |
| 2023 11 | 41 | 31 | 72 |
| 2023 10 | 31 | 57 | 88 |
| 2023 9 | 50 | 31 | 81 |
| 2023 8 | 23 | 11 | 34 |
| 2023 7 | 34 | 12 | 46 |
| 2023 6 | 40 | 23 | 63 |
| 2023 5 | 29 | 16 | 45 |
| 2023 4 | 18 | 12 | 30 |
| 2023 3 | 24 | 25 | 49 |
| 2023 2 | 18 | 13 | 31 |
| 2023 1 | 20 | 12 | 32 |
| 2022 12 | 28 | 20 | 48 |
| 2022 11 | 22 | 19 | 41 |
| 2022 10 | 25 | 14 | 39 |
| 2022 9 | 26 | 23 | 49 |
| 2022 8 | 21 | 13 | 34 |
| 2022 7 | 23 | 37 | 60 |
| 2022 6 | 23 | 31 | 54 |
| 2022 5 | 13 | 8 | 21 |
| 2022 4 | 23 | 18 | 41 |
| 2022 3 | 19 | 37 | 56 |
| 2022 2 | 17 | 18 | 35 |
| 2022 1 | 13 | 18 | 31 |
| 2021 12 | 22 | 27 | 49 |
| 2021 11 | 12 | 19 | 31 |
Show all
